Orthofix Med Inc Stock Price, News & Analysis

Orthofix Medical Inc. (NASDAQ:OFIX) will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:30 p.m. ET. CEO Jon Serbousek and CFO Doug Rice will lead the discussion. The chat will be followed by one-on-one meetings. A live audio webcast can be accessed on the Company's website.

Orthofix specializes in innovative medical devices and biologics for spine and orthopedics, aiming to enhance patient mobility. Its products are distributed in over 70 countries from its headquarters in Lewisville, Texas.

Orthofix Medical Inc. (NASDAQ: OFIX) continues its sponsorship of Olympic Gold Medalist Laura Wilkinson as she trains for the Tokyo Olympics. Wilkinson, a three-time U.S. Olympic diver, overcame cervical disc degeneration with a successful spine fusion using Orthofix technology. At 39, she returned to diving, aiming to compete in the U.S. Olympic Team Trials from June 6-13, 2021. Orthofix's mission centers on improving patient mobility, and they express pride in supporting Wilkinson's journey while promoting awareness about spine health.

Orthofix Medical Inc. (NASDAQ:OFIX) has launched the OSCAR PRO Ultrasonic Arthroplasty Revision System in the U.S. and Europe. This advanced system aims to improve joint revision surgeries by effectively removing cement from failed implants, addressing challenges faced with traditional methods. As the fourth generation of the OSCAR line, it features an enhanced user interface and new data collection capabilities. The system is significant for the treatment of failed joint replacements, which may require surgical intervention due to cement adhesion.

Orthofix Medical Inc (NASDAQ:OFIX) announced positive preliminary results from the three- and four-year follow-up of its M6-C artificial cervical disc study. The data will be presented at the ISASS annual meeting on May 14. Key findings include a mean Neck Disability Index (NDI) score of 10.9 at three years and 10.3 at four years for M6-C patients, compared to 17.2 and 19.2 for the ACDF group, respectively. The study highlights statistically significant pain score improvements in neck and shoulder/arm pain. The M6-C disc, approved by the FDA in 2019, validates the benefits of cervical disc arthroplasty.

Orthofix Medical announced FDA 510(k) clearance for its OrthoNext digital platform, designed for deformity analysis and preoperative planning in pediatric orthopedic procedures. This platform complements the JuniOrtho Plating System, which targets advanced deformity and trauma reconstruction for pediatric patients. The company is progressing with a full market launch of the JuniOrtho system in the U.S. and Europe. This innovative combination aims to enhance surgical planning and optimize patient outcomes in pediatric orthopedic care.

Orthofix Medical reported Q1 2021 net sales of $105.6 million, reflecting a 0.7% increase year-over-year. The company faced challenges from the pandemic and severe weather, resulting in a net loss of $(5.8) million or $(0.30) EPS. Adjusted EPS was $0.17, up from $0.09 in Q1 2020. Gross profit decreased to $79.7 million with a gross margin of 75.5%. Liquidity remains stable with $95.1 million in cash. The company anticipates 2021 net sales of $455 million to $465 million, marking a projected 11.9% to 14.4% increase.

Orthofix Medical Inc. (NASDAQ:OFIX) has entered into an exclusive license agreement with IGEA S.p.A to commercialize innovative orthopedic products in the U.S. and Canada. This includes obtaining FDA approvals for IGEA's bone and cartilage stimulation technologies, enhancing Orthofix's existing Pulsed Electromagnetic Field (PEMF) therapies. The collaboration aims to expand treatment options for fracture management and improve joint health. IGEA has a strong presence in Europe, treating over 20,000 patients annually, and this partnership will leverage both companies' strengths in the medical device market.

Orthofix Medical Inc. (NASDAQ:OFIX) announced it will release its financial results for the first quarter of 2021 on April 30, 2021, before market opening. A conference call led by CEO Jon Serbousek and CFO Doug Rice will occur at 8:30 a.m. ET the same day. Interested parties can join via phone or access the webcast on the company's investor relations site. Orthofix focuses on innovative medical devices for spine and extremities, distributing products in over 70 countries.

Orthofix Medical (NASDAQ: OFIX) has received FDA 510(k) clearance and successfully implanted its FORZA™ Ti TLIF Spacer System, designed for Transforaminal Lumbar Interbody Fusion. This 3D-printed titanium implant incorporates Nanovate™ Technology to promote bone growth during spinal fusion. Key features include optimized porosity and a large graft window. Orthofix aims to address current surgeon needs and enhance patient outcomes with this innovative system, building on the recent launch of its cervical interbody product. The product rollout will target specific commercial channels.